Edwards Lifesciences Corporation (NYSE:EW) Given Consensus Rating of "Moderate Buy" by Analysts

Key Points

• Analysts maintain a bullish outlook: Twenty-three brokerages give Edwards Lifesciences a consensus “Moderate Buy” rating, with 17 buys and six holds. The average 12-month price target is $100.27, above the reported share price of $89.33.
• Quarterly results exceeded expectations: Edwards reported earnings of $0.78 per share versus the $0.74 consensus estimate and revenue of $1.74 billion versus $1.70 billion expected. Revenue increased 13.6% year over year, while the company issued third-quarter and full-year 2026 EPS guidance.
• Insiders have been net sellers: Company executives sold 43,539 shares worth approximately $3.69 million over the past 90 days, while institutional investors own 79.46% of the stock.

Shares of Edwards Lifesciences Corporation (NYSE:EW - Get Free Report) have been given an average recommendation of "Moderate Buy" by the twenty-three brokerages that are presently covering the company, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a hold recommendation and seventeen have issued a buy recommendation on the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $100.2727.

Several equities research analysts have weighed in on the company. Royal Bank Of Canada increased their price objective on Edwards Lifesciences from $100.00 to $110.00 and gave the stock an "outperform" rating in a report on Monday, July 13th. Weiss Ratings reissued a "hold (c)" rating on shares of Edwards Lifesciences in a research note on Friday, July 17th. Mizuho upped their target price on Edwards Lifesciences from $100.00 to $105.00 and gave the company an "outperform" rating in a report on Wednesday, July 15th. Evercore reaffirmed an "outperform" rating and issued a $100.00 price target on shares of Edwards Lifesciences in a research note on Monday, July 6th. Finally, Canaccord Genuity Group set a $85.00 price target on shares of Edwards Lifesciences and gave the company a "hold" rating in a report on Friday, April 24th.

Edwards Lifesciences Price Performance

EW stock opened at $89.33 on Friday. The stock has a market capitalization of $51.44 billion, a price-to-earnings ratio of 51.34, a PEG ratio of 2.23 and a beta of 0.85. The firm's 50-day moving average price is $88.13 and its two-hundred day moving average price is $84.04. The company has a current ratio of 4.52, a quick ratio of 3.63 and a debt-to-equity ratio of 0.06. Edwards Lifesciences has a 12-month low of $72.30 and a 12-month high of $96.29.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, topping analysts' consensus estimates of $0.74 by $0.04. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The company had revenue of $1.74 billion during the quarter, compared to analyst estimates of $1.70 billion. During the same period in the prior year, the business posted $0.67 earnings per share. Edwards Lifesciences's revenue for the quarter was up 13.6% on a year-over-year basis. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, equities analysts predict that Edwards Lifesciences will post 3 earnings per share for the current year.

Insiders Place Their Bets

In other news, VP Daniel J. Lippis sold 620 shares of the firm's stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $81.14, for a total value of $50,306.80. Following the completion of the sale, the vice president directly owned 40,411 shares of the company's stock, valued at approximately $3,278,948.54. This trade represents a 1.51% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Donald E. Bobo, Jr. sold 23,145 shares of Edwards Lifesciences stock in a transaction dated Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total transaction of $2,000,190.90. Following the sale, the vice president directly owned 98,611 shares in the company, valued at $8,521,962.62. The trade was a 19.01% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 43,539 shares of company stock worth $3,685,364. 0.31% of the stock is currently owned by corporate insiders.

Institutional Trading of Edwards Lifesciences

Large investors have recently bought and sold shares of the company. Evermay Wealth Management LLC lifted its position in shares of Edwards Lifesciences by 4.0% during the fourth quarter. Evermay Wealth Management LLC now owns 3,304 shares of the medical research company's stock worth $282,000 after purchasing an additional 128 shares in the last quarter. Rehmann Capital Advisory Group grew its holdings in Edwards Lifesciences by 2.1% during the 4th quarter. Rehmann Capital Advisory Group now owns 6,399 shares of the medical research company's stock valued at $546,000 after purchasing an additional 130 shares in the last quarter. McIlrath & Eck LLC increased its stake in Edwards Lifesciences by 14.6% during the 4th quarter. McIlrath & Eck LLC now owns 1,057 shares of the medical research company's stock worth $90,000 after buying an additional 135 shares during the period. Quadrant Capital Group LLC lifted its holdings in Edwards Lifesciences by 0.9% in the 4th quarter. Quadrant Capital Group LLC now owns 15,113 shares of the medical research company's stock worth $1,288,000 after buying an additional 136 shares in the last quarter. Finally, Stephens Inc. AR lifted its holdings in Edwards Lifesciences by 5.4% in the 4th quarter. Stephens Inc. AR now owns 2,799 shares of the medical research company's stock worth $239,000 after buying an additional 144 shares in the last quarter. 79.46% of the stock is owned by institutional investors.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source